Skip to main content
. Author manuscript; available in PMC: 2024 Feb 2.
Published in final edited form as: Lancet Diabetes Endocrinol. 2023 Dec 4;12(1):39–50. doi: 10.1016/S2213-8587(23)00321-2

Figure 2. Absolute and relative effects of allocation to empagliflozin on ‘total slopes’ and ‘chronic slopes’, by pre-specified diabetes subgroup, and post-hoc expanded eGFR and uACR subgroups.

Figure 2

P values for test of heterogeneity between absolute differences in chronic slopes for patients with and without diabetes and tests for trend in absolute differences in chronic slope across eGFR and UACR categories are 0.0085, 0.0013 and <0.0001 respectively. P values for test of heterogeneity between absolute differences in total slopes for patients with and without diabetes and tests for trend in absolute differences in total slope across eGFR and UACR categories are 0.19, 0.023 and <0.0001 respectively.